Skip to main content
Article
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
Cancer Chemotherapy and Pharmacology (2012)
  • Miguel A. Villalona Calero, M.D.
Abstract
PURPOSE:
First-in-man study of KOS-1584, a second generation epothilone.
METHODS:
Patients with advanced solid malignancies received KOS-1584 every 3 weeks until disease progression. Using a modified Fibonacci dose escalation scheme, one patient was enrolled at each dose level until the first instance of grade 2 toxicity. Thereafter, a standard 3 + 3 design was utilized.
RESULTS:
Sixty-six patients in 14 cohorts were dosed from 0.8 to 48 mg/m(2). Diarrhea, arthralgias, and encephalopathy were dose-limiting toxicities (DLTs) at doses ≥36 mg/m(2). At the recommended phase II dose (RP2D), the most common adverse effects were peripheral neuropathy (low grade), fatigue, arthralgias/myalgias, and diarrhea (31, 6%). The incidence of neutropenia was low. The overall clearance, volume of distribution, and half-life of KOS-1584 were 11 ± 6.17 L/h/m(2), 327 ± 161 L/m(2), and 21.9 ± 8.75 h, respectively. The half-life for the seco-metabolite (KOS-1891) was 29.6 ± 13.8 h. KOS-1584 exhibited linear pharmacokinetics. A dose-dependent increase in microtubulin bundle formation was observed at doses ≥27 mg/m(2). Two patients achieved partial responses and 24 patients had stable disease (SD).
CONCLUSIONS:
The RP2D of KOS-1584 is 36 mg/m(2). The lack of severe neurologic toxicity, diarrhea, neutropenia, or hypersensitivity reactions; favorable pharmacokinetic profile; and early evidence of activity support further evaluation.
Publication Date
February, 2012
Citation Information
Miguel A. Villalona Calero. "Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors." Cancer Chemotherapy and Pharmacology Vol. 69 Iss. 2 (2012) p. 523 - 531
Available at: http://works.bepress.com/miguel-villalonacalero/71/